Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Projectdetails
Introduction
PRe-ART-2T will translate the FET-OPEN project PRe-ART (Predictive Reagent Antibody Replacement Technology) from laboratory proof-of-concept to investment readiness. We retain Pre-ART's original aim to disrupt the reagent antibody market, which, after over forty years, is still based on monoclonal antibodies (mAbs) to detect biomolecules. Notably, 50% of all commercial reagent mAbs have been shown to not function correctly.
Project Goals
Pre-ART has successfully delivered a foundational platform technology to TRL3. PRe-ART-2T will develop the technology to TRL6, empowering our aim to disrupt the reagent antibody market by:
- Replacing low-quality, commercial animal-derived reagent mAbs.
- Introducing high-performing synthetic alternatives created by combining modules from our encyclopaedia of experimentally pre-selected amino acid-binding motifs.
Methodology
Multidisciplinarity is key to the current experimental success of PRe-ART. By combining collective expertise in:
- Biochemistry
- Computational protein design
- Protein engineering
We have created a virtuous circle wherein:
- Biochemical & structural data (UZH) inform our novel computational mutagenic predictions (UBT).
- These predictions inform the synthesis of highly-specified gene libraries (Aston).
- The resulting protein products are analyzed through novel high-throughput screens (UZH).
Key hits are analyzed biochemically and structurally (UZH), and the resulting data inform the next cycle. As the cycle reiterates, greater specificity ensues.
Achievements
We have thus created many new and extremely stable amino acid-binding motifs that we have also combined in a modular manner to successfully bind predicted peptide targets. The project has also resulted in:
- Novel modeling (ATLIGATOR)
- Mutagenic (ParaMAX randomization)
- Screening procedures
Future Plans
In PRe-ART-2T, we will complete our suite of dArmRPs for natural and modified amino acids and further study their modularity by creating prototypes for four commercially relevant targets.
Investment Outlook
At the end of the PRe-ART-2T project, we expect to seek investment of approximately €20 million.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 800.000 |
Totale projectbegroting | € 800.000 |
Tijdlijn
Startdatum | 1-6-2022 |
Einddatum | 31-5-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAT BAYREUTHpenvoerder
- UNIVERSITAT ZURICH
- ASTON UNIVERSITY
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
INCYPRO: A key technology to enable the broad application of proteins in diagnostics and therapeuticsThe INCYPROnext project aims to validate a novel technology for stabilizing proteins, enhancing their utility in biotechnological and biomedical applications, targeting a $170B market. | EIC Transition | € 2.498.750 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
INCYPRO: A key technology to enable the broad application of proteins in diagnostics and therapeutics
The INCYPROnext project aims to validate a novel technology for stabilizing proteins, enhancing their utility in biotechnological and biomedical applications, targeting a $170B market.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORINGThe project aims to evaluate the commercial potential of a novel DNA-based platform for rapid and cost-effective detection of bispecific antibodies to monitor immunotherapy efficacy. | ERC POC | € 150.000 | 2022 | Details |
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeuticsThis project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein. | ERC STG | € 1.499.162 | 2024 | Details |
Engineering next-generation fusion proteins to dress the cell membrane with functionally enhanced receptorsDRESSCODE aims to revolutionize drug delivery by engineering recombinant proteins to enhance transmembrane receptors, enabling cost-effective therapies for angiogenesis and cancer immunotherapy. | ERC STG | € 1.497.778 | 2024 | Details |
REVisiting Antibody structures and repertoires through advances in Mass spectrometry and ProteomicsREVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses. | ERC ADG | € 2.500.000 | 2025 | Details |
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORING
The project aims to evaluate the commercial potential of a novel DNA-based platform for rapid and cost-effective detection of bispecific antibodies to monitor immunotherapy efficacy.
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeutics
This project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein.
Engineering next-generation fusion proteins to dress the cell membrane with functionally enhanced receptors
DRESSCODE aims to revolutionize drug delivery by engineering recombinant proteins to enhance transmembrane receptors, enabling cost-effective therapies for angiogenesis and cancer immunotherapy.
REVisiting Antibody structures and repertoires through advances in Mass spectrometry and Proteomics
REVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses.